APLT
Applied TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
APLT Profile
Applied Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets
Pharmaceutical
01/20/2016
05/14/2019
NASDAQ Stock Exchange
35
12-31
Common stock
545 Fifth Avenue, Suite 1400, New York, NY 10017
--
Applied Therapeutics, Inc., was incorporated in Delaware on January 20, 2016 and is headquartered in New York. The company is a clinical-stage biopharmaceutical company that develops a portfolio of new product candidates targeting potent molecular targets with unmet medical needs. The company's approach to drug development utilizes recent technological advances to design improved drugs, utilizes early use of biomarkers to confirm biological activity, and focuses on shortened regulatory pathways. The company's first molecular target is aldose reductase, or AR, an enzyme that converts glucose to sorbitol under oxidative stress conditions and is involved in a variety of diseases. The company's AR inhibitor or ARI program currently includes three small molecules, all of which are designed to be effective selective ARI and designed to have unique tissue permeability characteristics to target different disease states, including diabetic complications, heart disease and rare pediatric metabolic diseases. The company's ARI program application strategy, the company has also developed a program for the selective inhibition of phosphatidylinositol 3- kinase, or PI3K subunit, which has led to early oncology therapy.
